Daily consumption of orange juice may improve genes linked to cardiovascular well-being

A daily glass of orange juice can do more than refresh you. It can fine-tune thousands of genes linked to blood pressure and metabolism, with benefits varying according to your body weight.

Study: A global transcriptome analysis reveals body weight-related molecular responses to chronic orange juice consumption in healthy subjects. Image credit: Sunlight_s / Shutterstock

In a recent study published in the journal Molecular Nutrition & Food Researcha team of researchers investigated how chronic orange juice (OJ) intake affects the transcriptomes of peripheral blood mononuclear cells (PBMCs) in healthy adults and whether responses vary by body mass index (BMI) status. This was a preliminary intervention with one arm without a control drink. The findings show transcriptional associations and do not establish causation. Fold-change ranges for individual genes were reported in supplemental data but not highlighted in the main text.

Nutrogenomic Potential of Citrus Flavanones

What if a breakfast staple could quietly regulate the genes that drive blood pressure, lipids and inflammation? Citrus fruits, especially OJ, provide flavanones such as hesperidin and naringenin that may influence vascular tone, lipid handling, and immune signaling. However, most people question whether a daily glass actually changes biology in ways that matter, and whether body weight influences the response.

Mapping gene activity in circulating immune cells can link a kitchen habit to outcomes of interest in families, although the mechanistic paper did not recently evaluate clinical endpoints. Previous publications from the same cohort reported reductions in blood pressure and body fat percentage with 500 mL/day of OJ over 60 days.

Participant Profile and Study Design

Healthy adults (n = 20, 10 men, 10 women, 21–36 years) without chronic disease consumed 500 mL/day of pasteurized OJ for 60 days, divided into two home doses, after a 3-day citrus-free washout. Participants also avoided citrus foods during the intervention.

Fasting blood was drawn at baseline (T0) and day 60 (T60). PBMCs were isolated and total ribonucleic acid (RNA) was extracted. Global transcriptomes were plotted on Clariom D microarrays. Differentially expressed features were defined at a false discovery rate of p <0.05.

Multi-Omics and Computational Analyses

Pathway enrichment was performed using GeneTrail with the Kyoto Encyclopedia of Genes and Genomes (KEGG), WikiPathways and BioCarta. Protein-protein interaction networks were analyzed using the search tool to retrieve interacting genes/proteins (SERIES).

Predicted transcription factors were identified with Enrichr. MicroRNA (miRNAs) targets were obtained through Mienturnet/miRTarBase. long non-coding RNA (lncRNA) targets via LncRRIsearch. small nuclear RNA (snoRNA) changes were also recorded. Disease associations used the Comparative Toxicogenomics database.

Molecular docking of flavanone metabolites

In silicon Molecular docking (SwissDock) tested Phase II flavanone metabolites (for example, glucuronides/sulfates hesperetin and naringenin) and gut-derived catabolites against candidate transcription factors including nuclear factor kappa B (NF-κB) subunit 1, aryl hydrocarbon acceptor (AHR), activated by peroxisome proliferator receptor alpha (PARA), activating transcription factor 4 (ATF4), plasminogen activator, urokinase (PLAU), proto-oncogene (MYC), nuclear respiratory factor 1 (NRF1), Yin-Yang 1 (EU1), E26 especially for transformation (ETS) transcription factor ELK4 (ELP4), RELA (p65 subunit of NF-κB), retinoid X receptor alpha (RXRA), interferon regulatory factor 9 (IRF9), and tumor protein 53 (TP53). Subgroup analyzes were performed to contrast normal weight (NW) and overweight (OW) participants by BMI.

Transcriptional remodeling after orange juice intake

Chronic OJ intake reshaped the PBMC transcriptome: 3,790 oligonucleotides changed, including 1,705 protein-coding genes (mainly downstream), 66 miRNAs, 19 lncRNAs, and 67 snoRNAs. Principal components, partial least squares-discriminant analysis (PLS-DA), and clustering analyzes successfully separated T60 from T0, indicating a consistent interference signal.

Enriched pathways mapped to blood pressure control (aldosterone synthesis/secretion, renin secretion, angiotensin converting enzyme inhibitor-related signaling), lipid metabolism (thermogenesis, lipogenesis, mitochondrial fatty acid β-oxidation), inflammation (factor 1, interleukin).IL17)), cell adhesion (focal adhesion, actin cytoskeleton) and major signaling axes (mitogen-activated protein kinase (MAPK), vascular endothelial growth factor receptor 2 (VEGFR2), phosphoinositide 3-kinase-Akt (PI3K-Akt), epidermal growth factor (EGF) receptor, cyclic adenosine monophosphate (camp), insulin and advanced glycation end product – receptor for advanced glycation end products). Additional enrichment included AHR signaling and endoplasmic reticulum (ER) protein processing.

Protein-protein interaction nodes included serine/threonine kinase AKT1, glyceraldehyde 3-phosphate dehydrogenase (GAPDH), beta-catenin-1 (CTNNB1), heat shock protein 90 alpha (HSP90AA1), and eukaryotic elongation factor 2 (EEF2).

Gene-level modulation and non-coding RNA

Cardiometabolic relevance emerged at the gene level. Genes associated with blood pressure nicotinamide phosphoribosyltransferase (NAMPT) and NLR family pyrin domain containing 3 (NLRP3) were down-regulated, along with nuclear receptor subfamily 4 group A 2 (NR4A2), circadian regulator period 1 (PER1), salt-inducible kinase 1 (SIK1), G protein-coupled receptor 183 (GPR183), and serum/glucocorticoid-regulated kinase 1 (SGS1), aligning with mechanisms favoring blood pressure reduction.

Decreased inflammatory mediators: IL1B, IL6, prostaglandin-endoperoxide synthase 2 (PTGS2/COX-2), and G protein signaling regulator 1 (RGS1), consistent with decreased NF-κB activity and decreased cytokine tone.

Lipid/adipocyte programs were also altered: genes such as Kruppel-like factor 4 (KLF4), receptor-interacting serine/threonine-protein kinase 1 (RIPK1), perilipin-2 (PLIN2), and CXC chemokine ligand motif 8 (CXCL8) shifted to a profile associated with better metabolic control.

The non-coding layers reflect these trends. Among 66 altered miRNAs, species associated with weight loss (for example, miR-548, miR-1185-1 family) were increased, while inflammation-related miR-640 and miR-1248 were decreased. miR-1305 was increased, a change reported with anti-inflammatory effects.

19 lncRNAs were altered, including the downregulation of the small nuclear RNA host gene 16 (SNHG16) and up-regulation of apoptosis-related transcription in bladder cancer (AATBC), a regulator of human adipocyte plasticity. 67 snoRNAs were shifted, 61 of which were downregulated, including downregulated members of the RPL13A complex (SNORD U32/U33/U34/U35), a pattern associated with lower oxidative stress and inflammation.

Fold-change magnitudes for these RNA classes differed between transcripts, typically within a range of −1.5 to −8.0 for down-regulated features and +1.5 to +5.0 for up-regulated features, according to supplemental data. Disease mapping linked the signature to cardiovascular disease, hypertension, diabetes, obesity and disorders of glucose metabolism, highlighting clinical relevance.

BMI-Specific Transcriptional Differences

Overweight participants exhibited a unique alteration of lipid metabolism and adipogenesis pathways, characterized by distinct regulation of glycogen synthase kinase 3beta (GSK3B), G protein-coupled receptor kinase 6 (GRK6), and miRNAs, including miR-548i and miR-1292-3p. Normal-weight participants showed unique modulation of inflammatory pathways, characterized by changes in signal transducer and activator of transcription 3 (STAT3), solute carrier family 16 members 6 (SLC16A6), B-cell lymphoma 2 (BCL2), MAPK1 and miR-1185-2-5p. Thus, two people drinking the same OJ may have different molecular benefits depending on BMI.

Mechanistic plausibility of flavanone-gene interactions

Molecular docking supported direct interactions between Phase II flavanone metabolites (for example, hesperetin-3-glucuronide, hesperetin-7-glucuronide, hesperetin-3-sulfate; naringenin-4-glucuronide, naringenin-7-glucuronide) and transcription factors, including the transcription factors PFK4FPAR1, NFKBPAR1, NFKBPAR1, NFKBPAR1, NFKBPAR1, NFKFPAR1, N. PLAU, NRF1, IRF9, MYC, YY1, ELK4, RELA, RXRA, and TP53, with a free energy range of −6.29 to −9.63 kcal/mol. interactions <-6 kcal/mol were considered significant, offering a plausible pathway from juice metabolites to gene regulatory effects.

Clinical Interpretation and Research Perspectives

Daily OJ, a known food, reprogrammed immune cell gene networks associated with blood pressure, lipids, and inflammation, with multilevel changes in protein-coding genes, miRNA, lncRNA, and snoRNA. Predicted interactions between flavanone metabolites and transcription factors, including NFKB1, AHR, and PPARA, provide mechanistic plausibility.

Importantly, effects stratified by BMI revealed that lipid pathways predominated in overweight adults, whereas inflammatory pathways shifted in normal-weight adults. However, the results are limited by the small sample size (n=20), the absence of a control drink, the use of a microarray platform, and the exploratory nature of the in-silico connection, which is still hypothesis-generating.

Future studies should integrate multiple change size data with targeted functional assays to validate these transcriptional signatures. For individuals and clinicians, this supports tailoring “simple” dietary advice to body weight to turn a daily drink into a more precise cardiometabolic driver.

Personalized nutrition requires both molecular evidence and practical application. These findings offer early molecular insights that can provide such personalized nutritional guidance. Further research is needed to confirm and translate these transcriptional effects into clinical outcomes.